GlassScriptPhysician profile
Evan Shlofmitz
NPI 1639494479
$950,744.63
in general payments reported to CMS, 2019-2025
44 companies · $221K in 2025
The $221K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $25K · 2021: $116K · 2022: $187K · 2023: $184K · 2024: $194K · 2025: $221K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $349K · Consulting Fee: $105K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $55K · Honoraria: $36K · Travel and Lodging: $28K · Food and Beverage: $23K · Long Term Medical Supply Or Device Loan: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $348,616.94 |
| Consulting Fee | $105,288.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $55,300.00 |
| Honoraria | $36,260.00 |
| Travel and Lodging | $27,793.36 |
| Food and Beverage | $22,964.19 |
| Long Term Medical Supply Or Device Loan | $2,282.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236,567.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $150,200.42 | 2020-2024 | Xarelto |
| Abbott Laboratories | $130,030.11 | 2019-2025 | Optis, Ultreon, Coroflow |
| Shockwave Medical, INC | $113,374.70 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $99,932.81 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $45,969.18 | 2021-2025 | (9520) Igt Devices Undivided, Igt Devices Undivided, US Eq Undivided |
| Boston Scientific Corporation | $41,779.67 | 2019-2025 | General - Vascular Access, Avvigo Guidance System, Rotapro |
| Lexicon Pharmaceuticals, INC. | $36,487.56 | 2024 | Inpefa |
| Heartflow, INC. | $25,589.53 | 2024-2025 | |
| Medtronic Vascular, INC. | $12,843.27 | 2019-2020 | |
| Medtronic, INC. | $11,099.93 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Mycarelink |
| Chiesi USA, INC. | $10,234.99 | 2022-2023 | Kengreal |
| Cardiovascular Systems INC. | $6,080.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $5,819.29 | 2022-2024 | Farxiga |
| Acist Medical Systems, INC. | $5,520.92 | 2021-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opsens INC. | $4,000.00 | 2020-2023 | Savvywire |
| Janssen Global Services, LLC | $3,720.00 | 2022 | |
| Gentuity, LLC | $2,982.26 | 2024-2025 | Gentuity Hf-Oct Imaging System, Vis-Rx Prime, Vis-Rx |
| Terumo Medical Corporation | $2,430.02 | 2023-2025 | Glidesheath Slender, Metacross Otw, Heartrail |
| Spectrawave, INC | $1,829.56 | 2023-2025 | Hypervue Imaging System, Starlight Imaging Catheter, X1-Ffr |
| Cordis US Corp. | $541.67 | 2023 | Mynx Control |
| Cathworks, INC. | $467.88 | 2021-2024 | Ffrangio |
| Esperion Therapeutics, INC. | $458.82 | 2021-2025 | Nexletol, Nexlizet |
| Neovasc Medical INC | $427.98 | 2021 | |
| Penumbra, INC. | $366.03 | 2022 | |
| Biotronik INC. | $360.11 | 2022-2025 | Biomonitor, Acticor 7 Vr-T Dx, Nhancer Rx |
| Cardiva Medical, INC. | $261.29 | 2024-2025 | Savvywire, Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Abiomed | $202.84 | 2025 | |
| Cvrx, INC. | $139.80 | 2024 | Barostim Neo System |
| Inari Medical, INC. | $122.44 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.21 | 2020 | |
| Recor Medical INC | $118.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Arrow International, INC. | $118.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $87.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $84.40 | 2023-2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $77.52 | 2022-2023 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $72.32 | 2023-2024 | |
| Cardinal Health 200 LLC | $56.64 | 2019 | |
| Celonova Biosciences, INC. | $49.20 | 2020 | |
| Impulse Dynamics (USA) INC. | $38.09 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $29.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.41 | 2025 | |
| Edwards Lifesciences Corporation | $24.22 | 2025 | Sapien 3 Ultra Resilia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Shlofmitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.